Governance

The governance of the IMVACC MAS is constituted of :

– The Steering Committee

– The Scientific Committee

– Administrative coordinator:

Davide Mercuri

Davide Mercuri is the Program Coordinator of IMVACC since its inception.  He joined the Centre Hospitalier Universitaire Vaudois (CHUV) in May 2013 and serves the role of Grant Administrator for the Division of Immunology and Allergy (IAL) and the Swiss Vaccine Research Institute (SVRI). His main tasks consist in contributing to the financial management of the different research grants and the management of all administrative issues at the IAL and SVRI.

Davide Mercuri earned a commercial diploma and in 2012 and obtained a Federal Diploma of Higher Education as HR specialist.  During his career, he worked in positions as HR Specialist at the University of Lausanne and Figeas SA, a private health insurance company, which gave him a wealth of experience in HR management both in an academic and private environments.  Davide Mercuri speaks fluently in French, Italian and English.

Swiss Vaccine Research Institute (SVRI) and Division of Immunology & Allergy, Department of Medicine, CHUV, Lausanne

Tel: +4121 314 1872

The Steering committee is responsible for :

  • Development or modification of the IMVACC
    MAS bylaws and formal aspects of the
    curriculum.
  • Approval or amendment of the budget.
  • Admission of candidates to the IMVACC MAS,.
  • Decision to start training, depending on the
    number of candidates.
  • Proposals of granting the MAS title based on the proposal of the Scientific Committee.
  • Appointment of the program coordinator.
Steering committee:
Prof. F. Candotti

  • President of the Scientific committee
  • IMVACC program coordinator

After training in Medicine, Pediatrics, and Pediatric Allergy and Immunology at the Italian Universities of Brescia and Pavia, Prof. Candotti was granted a NIH Postdoctoral Fellowship in the laboratory of Dr. Michael Blaese at NCI and NHGRI before joining the Department of Pediatrics of the University of Brescia as an Assistant Professor in 1996 and eventually accepting a position at NHGRI that led to tenure at that institution in 2004. Ten years later, Prof. Candotti moved back to Europe to join the Division of Immunology and Allergy of the university Hospital of Lausanne in Switzerland, where he is Associate Professor of Medicine and Director of the Vaccine and Immunotherapy Center.
Throughout his career, Prof. Candotti focused on the study of the molecular basis of disorders of the immune system and the development gene therapy strategies for this heterogeneous group of diseases. He contributed to the discovery of JAK3-deficiency and AK2-deficiency as causes of SCID and performed extensive pre-clinical studies in the murine model supporting the feasibility of gene therapy for X-linked SCID and the Wiskott-Aldrich syndrome. From 2001 until 2014, Prof. Candotti co-led a series of gene therapy clinical trials for ADA-deficient SCID patients that studied the efficacy of different retroviral gene transfer vectors in humans.
Prof. Candotti has authored more than 110 peer-reviewed publications and numerous reviews and book chapters in the fields of immunodeficiency and gene therapy and is currently a member of the Editorial Board of the Journal of Clinical Immunology.

Dr. Pascale Dalla Piazza

  • Representative of UNIL-EPFL Continuing Education Foundation

Dr. Pascale Dalla Piazza, Scientific officer at the UNIL-EPFL Continuing Education Foundation

University of Lausanne (UNIL) and Swiss Technology Institute Lausanne (EPFL)

Prof. P.Bodenmann

Vice-Dean for Education at the Faculty of Biology and Medicine, University of Lausanne, Lausanne, Vaud, Switzerland.

Associate Professor and Holder of the Chair of medicine for vulnerable populations at the University of Lausanne in Switzerland. Senior Physician and Chief of the Department of Vulnerabilities and Social Medicine at Unisanté, Lausanne.

Prof. J.-P. Kraehenbuhl

  • Health Sciences eTraining (HSeT) Foundation representative

Jean-Pierre Kraehenbuhl, MD, is the Chief Executive Officer of the Health Sciences eTraining (HSeT) Foundation. He is emeritus Professor at the University of Lausanne and Consultant at the Division of Immunology & Allergy of the University Hospital (CHUV), Lausanne, Switzerland. His field of expertise is mucosal immunology and vaccinology. He is a member of EMBO and the scientific co-founder of Oravax, now Acambis Ltd.
Jean-Pierre Kraehenbuhl received an M.D. from the University of Lausanne, Switzerland in 1967 and a PhD in 1973. He completed a postdoctoral fellowship with George Palade at the Rockefeller University and subsequently became an assistant professor at Yale University School of Medicine. In 1975, he returned to the Institute of Biochemistry at the University of Lausanne, where he became a full professor in 1984. He joined the Swiss Institute of Cancer Research (ISREC) as a senior staff member, working on epithelial-cell membrane trafficking, mucosal immunity and mucosal vaccine design.

Prof. G. Pantaleo

  • Academic Director
  • SVRI representative
  • CHUV representative
  • Representative of the Faculty of Biology & Medicine Lausanne University 

Giuseppe Pantaleo, M.D., Professor of medicine, is Chief of the Division of Immunology and Allergy. He is also Chief of the Laboratory of AIDS Immunopathogenesis at the Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Switzerland. During the past ten years, Professor Pantaleo’s research has been focused on the delineation of the immunopathogenesis of HIV infection. His research activities have been focused on human T cell cloning, human T cell phenotypic and functional analysis, T cell activation, differentiation and memory, immunopathogenesis of HIV infection, HIV distribution in different anatomic compartments, antiretroviral therapy, immune reconstitution after antiretroviral therapy, immune-based therapeutic strategies and vaccines.

Professor Pantaleo is author and co-author of about 270 publications in international scientific journals.

Scientific committee:

Prof. F. Candotti

  • President
  • Program coordinator

After training in Medicine, Pediatrics, and Pediatric Allergy and Immunology at the Italian Universities of Brescia and Pavia, Prof. Candotti was granted a NIH Postdoctoral Fellowship in the laboratory of Dr. Michael Blaese at NCI and NHGRI before joining the Department of Pediatrics of the University of Brescia as an Assistant Professor in 1996 and eventually accepting a position at NHGRI that led to tenure at that institution in 2004. Ten years later, Prof. Candotti moved back to Europe to join the Division of Immunology and Allergy of the university Hospital of Lausanne in Switzerland, where he is Associate Professor of Medicine and Director of the Vaccine and Immunotherapy Center.
Throughout his career, Prof. Candotti focused on the study of the molecular basis of disorders of the immune system and the development gene therapy strategies for this heterogeneous group of diseases. He contributed to the discovery of JAK3-deficiency and AK2-deficiency as causes of SCID and performed extensive pre-clinical studies in the murine model supporting the feasibility of gene therapy for X-linked SCID and the Wiskott-Aldrich syndrome. From 2001 until 2014, Prof. Candotti co-led a series of gene therapy clinical trials for ADA-deficient SCID patients that studied the efficacy of different retroviral gene transfer vectors in humans.
Prof. Candotti has authored more than 110 peer-reviewed publications and numerous reviews and book chapters in the fields of immunodeficiency and gene therapy and is currently a member of the Editorial Board of the Journal of Clinical Immunology.

Prof. I. Knezevic

  • Professors, Teachers, Professionals experts

Dr Ivana Knezevic is Scientist in Technologies, Standards and Norms Team, and Group Lead of Norms and Standards for Biologicals in the Department of Essential Medicines and Health Products (EMP) in the World Health Organization (WHO), Switzerland.

Dr Ivana Knezevic has 22 years of professional experience in standardization, scientific and regulatory overview of biologicals. She joined WHO Biological Standardization Programme in September 2000. Since 2006, she has been leading the team for standardization of vaccines and some biological therapeutics in WHO Headquarters. Main aspects of the work include development and establishment of WHO International Standards as well as the assistance to regulators, manufacturers and other users of these standards.

In the area of biotherapeutics, she coordinated the development of WHO’s Guidelines on evaluation of Similar Biotherapeutic Products (SBPs), and organized a series of workshops to facilitate the implementation of guiding principles for evaluation of biotherapeutic products into regulatory and manufacturers’ practices.

Prof. J.-P. Kraehenbuhl

Jean-Pierre Kraehenbuhl, MD, is the Chief Executive Officer of the Health Sciences eTraining (HSeT) Foundation. He is emeritus Professor at the University of Lausanne and Consultant at the Division of Immunology & Allergy of the University Hospital (CHUV), Lausanne, Switzerland. His field of expertise is mucosal immunology and vaccinology. He is a member of EMBO and the scientific co-founder of Oravax, now Acambis Ltd.
Jean-Pierre Kraehenbuhl received an M.D. from the University of Lausanne, Switzerland in 1967 and a PhD in 1973. He completed a postdoctoral fellowship with George Palade at the Rockefeller University and subsequently became an assistant professor at Yale University School of Medicine. In 1975, he returned to the Institute of Biochemistry at the University of Lausanne, where he became a full professor in 1984. He joined the Swiss Institute of Cancer Research (ISREC) as a senior staff member, working on epithelial-cell membrane trafficking, mucosal immunity and mucosal vaccine design.

Prof. Yannick Muller

Swiss Federal Medical Diploma, Faculty of Medicine, University of Geneva, 2007
MD-PhD,  Potential of T regulatory cells to protect pancreatic islet grafts, University of Geneva, 2007-2011.
Residency in internal medicine, University Hospital of Geneva, 2011-2014. Residency in immunology and allergy 2014-2016, Residency in transplantation, University Hospital of Lausanne 2016-2017

Postdoctoral fellowship on cell therapies engineering, University California, San Francisco (UCSF) 2017- 2020

Senior attending physician in immunology and allergy, University Hospital of Lausanne,  2020-ongoing
Assistant Professor, tenure track, Faculty of Biology and Medicine, University of Lausanne,  2021-ongoing

Prof. Laurent Perez

Short CV

2003: PhD–Biochemistry at European Molecular Biology Laboratory. Heidelberg, Germany.

2004-2006: Post-Doc–Biophysics at European Molecular Biology Laboratory. Heidelberg. Germany.

2006-2010: Research scientist at Novartis Institutes for BioMedical Research. United Kingdom.

2011-2020: Principal investigator. Institutes for Research Biomedicine. Switzerland.

2020-to date: Professor (associate), Faculty of Biology and Medicine, University of Lausanne. Switzerland

 

The Scientific Committee’s competencies are :

  • Design of the curriculum and Implementation of the training modules.
  • Selection of candidates and their recommendation to the Steering Committee.
  • Proposals of granting diploma equivalences for decision of the Steering Committee.
  • Proposal of granting the MAS title for decision by the Steering Committee.
  • Proposal of eliminating students for decision by the Steering Committee.
  • Validation of the internship of the participants and validation of the master’s thesis topic of the participants.